Details for Patent: 12,208,109

Which drugs does patent 12,208,109 protect, and when does it expire?

Patent 12,208,109 protects AKYNZEO and is included in one NDA.

This patent has forty-six patent family members in thirty-seven countries.

Summary for Patent: 12,208,109

Title:	Physiologically balanced injectable formulations of fosnetupitant
Abstract:	Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
Inventor(s):	Alessio Venturini, Roberta Cannella
Assignee:	Helsinn Healthcare SA
Application Number:	US17/986,934
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 12,208,109

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	POWDER;INTRAVENOUS	210493-001	Apr 19, 2018		DISCN	Yes	No	12,208,109		Y
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes	12,208,109		Y

International Family Members for US Patent 12,208,109

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	108676
Australia	2017276588
Brazil	112018074655
Canada	3025837
Chile	2018003338
China	109310627
Colombia	2018011686